Lundbeck Delivering On The Financials, But Needs Some Positive Clinical Drivers

2025-05-16 06:52:39 ET

Summary

• Lundbeck's shares have declined due to U.S. policy risks and a perceived clinical setback, but core financial performance remains strong with solid Q1 results.
• Near-term upside hinges on regulatory success for Rexulti's PTSD indication, which could add $1B+ in annual sales if approved.
• Pipeline risks and upcoming patent expirations temper near-term growth, but late-stage assets offer meaningful long-term potential if successful.
• Despite risks, I see Lundbeck as undervalued by over 35%, but patience is needed as positive clinical/regulatory catalysts are required for sustained upside.

The last few months have not been the best for the shares of Danish drugmaker H. Lundbeck A/S (HLBBF) (HLUBF) (HLUNa.CO) (HLUNb.CO), as concerns about tariffs and challenges to prices in the U.S., coupled with a disappointing clinical update, have combined to drive a roughly 15% decline in the local share price since my last update , a little worse than the performance of the broader European pharmaceutical sector (as measured by the STOXX Europe Total Market Pharmaceuticals index)....

Read the full article on Seeking Alpha

For further details see: